Official websites use. Share sensitive information only on official, secure websites. Competing Interests: The authors have declared that no competing interests exist. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Evidence of outcomes of pubertal suppression in GD is limited.
We undertook an uncontrolled prospective observational study of GnRHa as monotherapy in 44 12β15 year olds with persistent and severe GD.
Semistructured interviews were conducted on GnRHa. All had normal karyotype and endocrinology consistent with birth-registered sex.
All achieved suppression of gonadotropins by 6 months. Most participants reported positive or a mixture of positive and negative life changes on GnRHa. Anticipated adverse events were common. Overall patient experience of changes on GnRHa treatment was positive. We identified no changes in psychological function. Changes in BMD were consistent with suppression of growth.
Larger and longer-term prospective studies using a range of designs are needed to more fully quantify the benefits and harms of pubertal suppression in GD. GD [ 1 ] in children and young people, also known as Gender Incongruence [ 2 ] and previously known as Gender Identity Disorder GID , is associated with considerable distress or impairment in social, school or other important areas of functioning [ 3 , 4 ].
